OnKure Therapeutics, Inc.
OKURHealthcare|Biotechnology|US
$2.87
+0.34 (+13.47%)
DCF Value
$4.23
Tangible Book / Share
$3.16
Cash / Share
$3.27
Analyst Consensus
Buy2 analysts
Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0
Consensus Target
$14.00
Implied Upside
+388.7%
Low Target
$14.00
High Target
$14.00
Price Target Trend
Last Month
—
0 targets
Last Quarter
$14.00
1 target · +389% vs price
Last Year
$14.00
1 target · +389% vs price
All Time
$24.50
2 targets · +755% vs price
Rating Trend
Dec 25
7 buy · 0 hold · 0 sell
Jan 26
6 buy · 0 hold · 0 sell
Feb 26
6 buy · 0 hold · 0 sell
Mar 26
6 buy · 0 hold · 0 sell
Apr 26
6 buy · 0 hold · 0 sell
May 26
6 buy · 1 hold · 0 sell
Jun 26
5 buy · 1 hold · 0 sell
Jul 26
5 buy · 1 hold · 0 sell
Aug 26
5 buy · 1 hold · 0 sell
Sep 26
5 buy · 1 hold · 0 sell
Oct 26
5 buy · 1 hold · 0 sell
Nov 26
5 buy · 1 hold · 0 sell
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Oppenheimer | maintain | Outperform | Aug 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 20, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 16, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 26, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 18, 2025 |
| Oppenheimer | maintain | Outperform | Mar 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 8, 2024 |
Earnings History
Next report: Mar 11, 2027 · EPS est. $-0.30| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $-0.36 | $-0.41 | — | $166.7K |
| Aug 4, 2026 | $-0.31 | $-0.54 | — | $166.7K |
| May 5, 2026 | $-1.11 | $-0.81 | — | $166.7K |
| Mar 12, 2026 | $-0.99 | $-1.15 | — | $16.0M |
| Nov 6, 2025 | $-1.09 | $-1.20 | — | — |
| Aug 12, 2025 | $-1.14 | $-1.23 | — | — |
| May 6, 2025 | $-1.19 | $-1.32 | — | — |
| Mar 10, 2025 | $-1.37 | $-0.86 | — | — |
News
OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
-- Announces PANORAMA, an OnKure-sponsored, large-scale, multiregional registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies
Nov 4, 2026globenewswire.com
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior management will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference being held in New York on September 14 – 16, 2026.
Aug 31, 2026globenewswire.com